I2032
Monoclonal Anti-Insulin-Like Growth Factor Binding Protein-1 antibody produced in mouse
clone 33627.11, purified immunoglobulin, lyophilized powder
Synonym(s):
Anti-IGFBP-1
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
biological source
mouse
Quality Level
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
33627.11, monoclonal
form
lyophilized powder
species reactivity
human
technique(s)
capture ELISA: suitable
neutralization: suitable
western blot: 1-2 μg/mL
isotype
IgG1
UniProt accession no.
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... IGFBP1(3484)
General description
The effects of insulin-like growth factors (IGF) are modulated by a family of insulin-like growth factor binding proteins 1-6. (IGFBPs -1-6). IGFBP-1 is secreted as an endocrine factor by liver, kidneys, decidua and in human amniotic fluid, but has the ability to signal in autocrine and paracrine fashion. Post-translational modifications such as ubiquitination, glycosylation and phosphorylation alter the activity of IGFBPs. Phosphorylation of IGFBP-1 is mainly mediated by Casein kinase I and II and cAMP-dependent protein kinases. IGFBP-1 alters the bioavailability of IGF in the serum by binding and sequestration so that a regulated amount id available to act on the target cells. The functions of IGFBP-1 are most important in the physiology of female reproductive system in mammals, for growth and development of the developing fetus
Monoclonal Anti-Human Insulin-like Growth Factor Binding Protein-1 (IGFBP-1) recognizes recombinant human IGFBP-1. No cross-reactivity is seen with recombinant human IGFBP-2, IGFBP-3, and IGFBP-4.
Monoclonal Anti-Human Insulin-like Growth Factor Binding Protein-1 (IGFBP-1) recognizes recombinant human IGFBP-1. No cross-reactivity is seen with recombinant human IGFBP-2, IGFBP-3, and IGFBP-4.
Specificity
The biological activity is measured by its ability to neutralize recombinant human IGFBP-1 in the presence of recombinant human IGF-I.
Immunogen
purified recombinant human insulin-like growth factor binding protein 1, expressed in E. coli.
Application
Anti- Insulin-Like Growth Factor Binding Protein-1 antibody may be used for immunoblotting at a working concentration of 1-2 μg/ml. For ELISA, a working concentration of 2 μg/ml may be used. The antibody is suitable for neutralization reactions (ND50 is 10-40 μg/ml).
Physical form
Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Terry J Smith
Pharmacological reviews, 62(2), 199-236 (2010-04-16)
This topically limited review explores the relationship between the immune system and insulin-like growth factors (IGF-I and IGF-II) and the proteins through which they act, including IGF-I receptor (IGF-IR) and the IGF-I binding proteins. The IGF/IGF-IR pathway plays important and
D J Fowler et al.
Human reproduction update, 6(5), 495-504 (2000-10-25)
Insulin-like growth factor-1 (IGFBP-1) is particularly important in human female reproductive physiology, where it is involved with other factors in a complex system which regulates menstrual cycles, puberty, ovulation, decidualization, implantation and fetal growth. This has implications for clinical obstetrics
M Westwood
Reviews of reproduction, 4(3), 160-167 (1999-10-16)
Insulin-like growth factors and their binding proteins are key regulators of fetal and maternal tissue growth and development during human pregnancy. Insulin-like growth factors, particularly IGF-II, are produced in abundance by the trophoblast cells of the placenta, whereas one of
K M Kelley et al.
The international journal of biochemistry & cell biology, 28(6), 619-637 (1996-06-01)
The IGFBPs are a family of homologous proteins that have co-evolved with the IGFs and that confer upon the IGF regulatory system both functional and tissue specificity. IGFBPs are not merely carrier proteins for IGFs, but hold a central position
Ali Vaziri-Gohar et al.
Molecular and cellular endocrinology, 422, 160-171 (2015-12-23)
Tamoxifen, a selective estrogen receptor modulator, is a commonly prescribed adjuvant therapy for estrogen receptor-α (ERα)-positive breast cancer patients. To determine if extracellular factors contribute to the modulation of IGF-1 signaling after tamoxifen treatment, MCF-7 cells were treated with IGF-1 in
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service